Aurobindo Pharma Limited, an India-based pharmaceutical company, announced the appointment of T. Vijaya Kumar as President – R&D (Specialty Drug Delivery), with effect from April 5, 2024. According to the company’s exchange filing, “Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby inform that upon recommendation of…
Aurobindo Pharma Limited announced the appointment of N. Ravikiran as Chief Business Officer of the company, with effect from March 5, 2024. According to the company’s exchange filing, “Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that upon recommendation of the Nomination and Remuneration Committee, the…
Aurobindo Pharma Limited announced the re-appointment of Girish Paman Vanvari as an Independent Director on the company’s Board, with effect from November 5, 2022. According to the company’s exchange filing, “We hereby inform that based on the recommendation of Nomination, Remuneration and Compensation Committee and subject to the approval of the members of the Company…
Aurobindo Pharma Limited (Aurobindo) announced that its subsidiary CuraTeQ Biologics Pvt Ltd. (CuraTeQ) has expanded the scope of its marketing and distribution agreement with Orion Corporation (Orion) to commercialize its biosimilars pipeline to include the Baltic states in Europe. Earlier in 2020, CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution…
Aurobindo Pharma announced that it has entered into a share purchase agreement to acquire 100% equity share capital of MViyeS Pharma Ventures Private Limited (MViyeS). The acquisition was completed on November 6, 2020, the company said in its press release. Before acquisition, MViyeS was holding 32.18% shareholding in Eugia Pharma Specialities Limited, a joint venture…